Earnings Per Share
EPS (Diluted)
Neurocrine Biosciences EPS (Diluted) increased by 29.1% to $1.91 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2287.5%, from $0.08 to $1.91. Over 4 years (FY 2021 to FY 2025), EPS (Diluted) shows an upward trend with a 47.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementIncome Statement
SectionEarnings Per Share
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
Higher values indicate stronger profitability even when accounting for potential share dilution.
Detailed definition
Calculated by dividing net income by the weighted-average number of common shares outstanding, assuming the conversion o...
Peer comparison
Used by all public companies to provide a realistic view of earnings per share for investors.
Metric ID:
eps_dilutedHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.43 | $0.23 | $0.00 | $0.14 | -$0.18 | $0.69 | $0.89 | -$0.79 | $0.95 | $0.82 | $1.46 | $0.42 | $0.63 | $1.24 | $1.00 | $0.08 | $1.06 | $2.04 | $1.48 | $1.91 |
| QoQ Change | — | -46.5% | -100.0% | — | -228.6% | +483.3% | +29.0% | -188.8% | +220.3% | -13.7% | +78.0% | -71.2% | +50.0% | +96.8% | -19.4% | -92.0% | >999% | +92.5% | -27.5% | +29.1% |
| YoY Change | — | — | — | — | -141.9% | +200.0% | — | -664.3% | +627.8% | +18.8% | +64.0% | +153.2% | -33.7% | +51.2% | -31.5% | -81.0% | +68.3% | +64.5% | +48.0% | >999% |
Range-$0.79 – $2.04
CAGR+36.9%
Avg YoY Growth+175.4%
Median YoY Growth+51.2%
EPS (Diluted) at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's eps (diluted)?
- Neurocrine Biosciences (NBIX) reported eps (diluted) of $1.91 in Q1 2026.
- How has Neurocrine Biosciences's eps (diluted) changed year-over-year?
- Neurocrine Biosciences's eps (diluted) increased by 2287.5% year-over-year, from $0.08 to $1.91.
- What is the long-term trend for Neurocrine Biosciences's eps (diluted)?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's eps (diluted) has grown at a 47.3% compound annual growth rate (CAGR), from $0.99 to $4.66.
- What does eps (diluted) mean?
- Earnings per share calculated as if all potential shares were issued.